全球单株抗体市场规模、份额、趋势和成长分析报告（2026-2034年）

单株抗体市场预计将从 2025 年的 3,065.3 亿美元成长到 2034 年的 8,171.4 亿美元，2026 年至 2034 年的复合年增长率为 11.51%。

随着单株治疗方法在现代医学中日益重要，全球单株抗体市场正经历快速成长。单株抗体是实验室合成的分子，旨在靶向体内特定抗原。它们被广泛用于治疗多种疾病，包括癌症、自体免疫疾病和感染疾病，是先进生物疗法的关键组成部分。

慢性病盛行率的上升和对标靶治疗需求的日益增长推动了市场成长。单株抗体疗法比传统治疗方法更精准，并改善了许多患者的治疗效果。此外，生物技术和基因工程的不断进步也推动了更有效的抗体药物的研发。

随着研发活动的不断拓展，单株抗体市场前景十分光明。製药公司正大力投资生物製药的研发，从而不断扩充抗体治疗方法的产品线。随着医疗体係日益重视个人化医疗和先进疗法，单株抗体有望在未来的医学创新中发挥关键作用。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球单株抗体市场：依来源划分

• 市场分析、洞察与预测
• 小鼠来源
• 嵌合体体
• 人性化
• 人类

第五章 全球单株抗体市场：依生产类型划分

• 市场分析、洞察与预测
• In Vivo
• In Vitro

第六章 全球单株抗体市场：依应用划分

• 市场分析、洞察与预测
• 肿瘤学
• 自体免疫疾病
• 感染疾病
• 神经系统疾病
• 其他的

第七章 全球单株抗体市场：依最终用途划分

• 市场分析、洞察与预测
• 医院
• 专业医疗中心
• 其他的

第八章 全球单株抗体市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Merck & Co. Inc
  • Pfizer Inc
  • Novartis AG
  • AstraZeneca Plc
  • Roche Diagnostics（F. Hoffmann La Roche Ltd.）
  • Johnson & Johnson Services Inc
  • Eli Lilly And Company
  • Abbott Laboratories
  • Bayer AG
  • Amgen Inc
  • GlaxoSmithKline Plc
  • Merck KGaA
  • Sanofi SA
  • Daiichi Sankyo Company
  • Limited
  • Viatris Inc

The Monoclonal Antibodies Market size is expected to reach USD 817.14 Billion in 2034 from USD 306.53 Billion (2025) growing at a CAGR of 11.51% during 2026-2034.

The global monoclonal antibodies market is experiencing rapid growth as these therapies become increasingly important in modern medicine. Monoclonal antibodies are laboratory-produced molecules designed to target specific antigens in the body. They are widely used in the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases, making them a key component of advanced biological therapies.

The growth of this market is driven by the increasing prevalence of chronic diseases and the rising demand for targeted treatment options. Monoclonal antibody therapies offer higher precision compared to traditional treatments, improving treatment outcomes for many patients. Additionally, continuous advancements in biotechnology and genetic engineering are enabling the development of more effective antibody-based drugs.

The future outlook for the monoclonal antibodies market is highly promising as research and development activities continue to expand. Pharmaceutical companies are investing heavily in biologic drug development, leading to a growing pipeline of antibody-based therapies. As healthcare systems focus on personalized medicine and advanced treatments, monoclonal antibodies are expected to play a major role in future medical innovation.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Source Type

• Murine
• Chimeric
• Humanized
• Human

By Production Type

• In Vivo
• In Vitro

By Application

• Oncology
• Autoimmune Diseases
• Infectious Diseases
• Neurological Diseases
• Others

By End Use

• Hospitals
• Specialty Centers
• Others

COMPANIES PROFILED

• Merck Co Inc, Pfizer Inc, Novartis AG, AstraZeneca plc, Roche Diagnostics F Hoffmann La Roche Ltd, Johnson Johnson Services Inc, Eli Lilly and Company, Abbott Laboratories, Bayer AG, Amgen Inc, GlaxoSmithKline plc, Merck KGaA, Sanofi SA, Daiichi Sankyo Company, Limited, Viatris Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL MONOCLONAL ANTIBODIES MARKET: BY SOURCE TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Source Type
• 4.2. Murine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Chimeric Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Humanized Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Human Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL MONOCLONAL ANTIBODIES MARKET: BY PRODUCTION TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Production Type
• 5.2. In Vivo Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. In Vitro Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL MONOCLONAL ANTIBODIES MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Autoimmune Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Neurological Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL MONOCLONAL ANTIBODIES MARKET: BY END USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End Use
• 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Specialty Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL MONOCLONAL ANTIBODIES MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Source Type
  • 8.2.2 By Production Type
  • 8.2.3 By Application
  • 8.2.4 By End Use
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Source Type
  • 8.3.2 By Production Type
  • 8.3.3 By Application
  • 8.3.4 By End Use
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Source Type
  • 8.4.2 By Production Type
  • 8.4.3 By Application
  • 8.4.4 By End Use
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Source Type
  • 8.5.2 By Production Type
  • 8.5.3 By Application
  • 8.5.4 By End Use
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Source Type
  • 8.6.2 By Production Type
  • 8.6.3 By Application
  • 8.6.4 By End Use
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL MONOCLONAL ANTIBODIES INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Merck & Co. Inc
  • 10.2.2 Pfizer Inc
  • 10.2.3 Novartis AG
  • 10.2.4 AstraZeneca Plc
  • 10.2.5 Roche Diagnostics (F. Hoffmann La Roche Ltd.)
  • 10.2.6 Johnson & Johnson Services Inc
  • 10.2.7 Eli Lilly And Company
  • 10.2.8 Abbott Laboratories
  • 10.2.9 Bayer AG
  • 10.2.10 Amgen Inc
  • 10.2.11 GlaxoSmithKline Plc
  • 10.2.12 Merck KGaA
  • 10.2.13 Sanofi S.A
  • 10.2.14 Daiichi Sankyo Company
  • 10.2.15 Limited
  • 10.2.16 Viatris Inc